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Abstract
This document is the result of an European Consensus conference which took place in Artimino, Tuscany, Italy, in March 2001
involving 33 experts on nutrition in patients with cystic fibrosis, organised by the European Cystic Fibrosis Society, and sponsored
by Axcan-Scandipharm, Baxter, Dr Falk Pharma, Fresenius, Nutricia, SHS International, Solvay Pharmaceuticals (major sponsor).
The purpose of the conference was to develop a consensus document on nutrition in patients with cystic fibrosis based on current
evidence.  2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is a world-wide disease occurring
in virtually all ethnic groups. In Caucasians it is the
most common lethal hereditary disorder with autosomal
recessive inheritance w1x. Approximately 1 in 25 are
heterozygous carriers, while the incidence of clinical
disease is approximately 1 in 2500 live births w1x. The
condition is caused by mutations in a single gene of
chromosome 7, which encodes the CF transmembrane
conductance regulator (CFTR) w2x. The CFTR protein
is a membrane bound cAMP-regulated chloride channel,
which is thought to regulate other cell membrane ion
channels w3x. More than 1000 different mutations have
been identified so far; however, a deletion of phenylal-
anine in the amino acid position 508 is present in
approximately 66% of chromosomes of all patients with
CF world-wide.
CFTR mutations affect epithelial ion and water trans-
port mainly in cells in the respiratory, gastrointestinal,
hepatobiliary, reproductive tracts and sweat glands. The
lack of chloride secretion in the pancreatic duct is
responsible for obstruction and autodigestion of the
pancreas early in embryonic life leading to severe
exocrine pancreatic insufficiency in approximately 85%
of CF newborns. In addition, intestinal obstruction com-
plicates the neonatal period in 10–15% of the infants.
Both inadequately treated pancreatic insufficiency and
intestinal obstruction were held responsible for a high
morbidity and mortality rate in patients with CF before
1970. As a result of various factors including better
neonatal care, surgery, antibiotic treatment of pulmonary
complications and improved nutrition, the median sur-
vival time of the patients has increased over the last
three decades from 10 to 30 years. Nevertheless, it is
still not clear to what extent improved nutritional status
contributes to increased survival. In a recent report
wasting was shown to be a significant predictor of
survival in patients with CF independent of lung func-
tion, arterial blood oxygen and carbon dioxide tensions
w4x. The fact that there is a remarkably close relationship
between body weight and lung function and that terminal
patients with CF are almost always severely malnour-
ished, suggests that good nutritional care is of benefit
for the patient with cystic fibrosis.
2. Nutritional deficiencies in CF
2.1. Nutrition and growth of individuals with CF
2.1.1. Growth during infancy
The mean birth weight of CF populations has been
reported as subnormal (CF males: 3.18 kg, females:
3.04 kg; unaffected males: 3.37 kg, females: 3.25 kg)
w5x. However, others have failed to confirm the finding
of lower birth weights in CF w6,7x.
Another study found children with CF to have a
reduced length (y1.24 standard deviation, S.D.) weight
(y0.72 S.D.) and head circumferences (y1.82 S.D.)
compared with controls w8x. However, these data may
not be representative since 34.6% of the infants were
affected by meconium ileus, which is associated with
worse outcomes w8x.
The early growth pattern of infants with CF is
dependent on both the age at diagnosis and the quality
of the subsequent treatment they receive. The majority
have pancreatic insufficiency and experience early gas-
trointestinal symptoms, which if not adequately treated
can lead to subnormal weight gain. Even some infants
diagnosed by neonatal screening have subnormal growth
throughout the first year if the start of treatment is
delayed by more than a few weeks after birth w9x.
2.1.2. Growth after infancy
Subsequent growth velocity of CF infants is usually
normal if chest infections are prevented or effectively
treated and the intestinal malabsorption is adequately
treated w6,7x. Almost normal growth and weight gain
was maintained throughout childhood in Canadian
patients with CF w10x and in 51 Swedish children with
CF height gain was normal between 5 and 8 years w11x.
The authors conclude that subnormal growth in infancy
can be compensated for by catch-up growth thereafter.
In Australian patients growth, weight and respiratory
function were better at the age of 10 years in a group
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of screened patients than in those born before screening
was introduced w12x.
As a consequence of patient registries, data from
larger numbers of patients with CF are available for
epidemiological investigations. In 1998 the Cystic Fibro-
sis Foundation (CFF) reported that 12.7% of children
and 21.6% of adults were below 85% weight for height
w13x. Comparable median centile values for Canadian
and American patients with CF were: for height 28 and
21, respectively, weight 27 and 22, respectively, but
both were 103% of ideal weight for height w14x. Data
from the UK CF registry revealed that the mean weight
S.D. scores of the males were between y0.25 and y
0.5 until the age of 10 years after which they declined
as did the body mass index (BMI). The mean weight
S.D. scores of females were approximately y0.5 but
they had a declining BMI after the age of 5 years
w15,16x. After 10 years there was a progressive decline
in SD scores for both height and weight. This deterio-
ration in S.D. scores after the age of 10 years could be
explained by some delay in the onset of puberty.
However, it is more likely to be a reflection of an
overall deterioration associated with an increase in the
severity of the pulmonary disease.
It is increasingly apparent that the condition of the
patients is closely related to the treatment they receive
and that patients may be in a better nutritional state in
clinics where regular attention is paid to nutrition and
growth. It is encouraging that the nutritional state of
new patients with CF has steadily improved over the
years w17x.
2.1.3. Delayed puberty and growth spurt
There is delay in the onset of puberty and menarche
in patients with CF who have significant nutritional
problems w18–20x; even in well-nourished females some
delay has been reported w19x. Surprisingly the delay in
skeletal maturation is modest in most patients with CF
and seems to increase with age, as pulmonary problems
become more severe w5x.
3. Malnutrition: definition and assessment
3.1. Evaluation of nutrition and growth: anthropometry
3.1.1. Weight and height
The patient should see an experienced doctor at every
visit and the specialist CF dietician at most clinic visits
and always if weight progress is unsatisfactory w21,22x.
Weight and height should be accurately measured at
each clinic attendance by trained clinic staff w23x; these
measurements should be charted to assess progress and
compared to reference values w24–27x. Caution should
be exercised when different anthropometric standards
are compared w28x. Values are expressed either as (per)
centiles, as percentage of the normal values for age or
as standard deviation (S.D.) or Z scores. Percentage
weight for height, weight for age and height for age are
often used when expressing the nutritional status of
children and are preferred to body mass index (BMI).
The measurements are calculated from the standard
equation:
Ž .Current weight kg
Ž .Weight kg equivalent to current height percentile
=100
When considering S.D. scores, for a population whose
values are normally distributed, the relationship of per-
centiles and S.D. scores are as follows: y2.0 S.D.
(2.28th centile), 0 S.D. (50th centile), q2.0 S.D.
(97.72nd centile) w24x.
3.1.2. The body mass index (BMI)
The BMI (weight wkgxyheight wm x) shows a reason-2
able correlation to body fat mass in adults, but less so
in children, and is in the first place used to quantify
obesity. Some adult CF clinics use BMI as a measure
of nutritional state in their patients whose growth has
ceased. Recently BMI categories for adults have been
redefined as underweight (-18.5), ideal (18.5–24.9),
pre-obese (25.0–29.9) and obese (G30.0) w29x. In
children BMI values must be interpreted on the basis of
comparison with age and gender specific reference
centiles w30x or S.D. scores. A low BMI without defi-
cient fatness will be found in patients with proportion-
ately long limbs and a short trunk, where there is poor
musculature or in adolescents with delayed puberty w24x.
In children and adolescents, no advantage has been
shown of using BMI, rather than weight for height, for
documenting malnutrition.
3.1.3. Other measurements
The mid upper arm circumference and skinfold meas-
urements w31x are held inappropriate for the detailed
monitoring required in CF w32x. Noting the stages of
breast, pubic hair and genital development and recording
the age of the menarche in girls are important as a
measure of the stage of development w25x for the correct
interpretation of changes in weight and height gain
during adolescence. Thus, after the age of 10 years
knowledge of the puberty state is required to adequately
assess growth and nutrition. More sophisticated methods
of measuring body composition, that are used primarily
for research purposes, offer more accurate assessment
of nutritional status and growth response to nutritional
therapy. These methods include total body potassium
w33,34x, total body electrical conductivity, bioelectrical
impedance analysis w35x, total body water by isotope
dilution and dual energy X-ray absorptiometry w36x.
Osteopenia and osteoporosis have been described in
both adults and children with CF w37,38x. Bone mineral
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Table 1
Guidelines for nutritional intervention. In case of malnutrition or weight loss there should be a full re-evaluation of all possible causes that affect
nutritional state. If nutritional intervention is indicated the following guidelines can be used. First enhance nutritional densityyoptimal intake
before starting supplements
-2 years 2–18 years )18 years
Normal nutritional state % wt.yht 90–110 % wt.yht 90–110 BMI 18.5–25 or
Preventive counselling no recent wt. loss
Dietetic referral indicated Any degree of failure %wt.yht 85–89 or BMI -18.5 or
Consider supplements to thrive wt. loss over 4-6 months or 5% wt. loss over -2 months
plateau in wt over 6 months
Invasive nutritional Failure to thrive despite Supplements tried and either: Supplements tried and either:
support oral supplementation %wt.yht -85 or BMI-18.5 or
wt. falling 2 centile positions )5% wt. loss over -2 months
For all age categories pay special attention if stunting is evident as defined: (1) height centile -0.4th; (2) Htyage -90%.
density (BMD) is best determined by dual energy X-
ray absorptiometry (DEXA). DEXA scans, which can
simultaneously assess fat mass and lean body mass, can
be carried out in most major CF units, and should be
considered as part of the nutritional assessment in all
patients over the age of 10 years, but there is no
documented evidence of the benefit of regular DEXA
scans that are followed by targeted intervention.
3.1.4. Rate of weight gain and growth
The weight for height should remain above 90% and
ideally should be over 95%. Oral energy supplements
are usually advised if the weight for height is between
85 and 90% in children or the BMI is less than 18.5 in
adults and enteral tube feeding if weight for height falls
below 85% or BMI is less than 18.5, despite trying oral
energy supplements (see Table 1). Other causes of
abnormal nutrition and growth include either gastroin-
testinal disorders such as food intolerance, coeliac dis-
ease or inflammatory bowel disease w39x or even
endocrine disorders w40x. Oral or long-term inhaled
steroid therapy w41x may cause a slowing of height gain
in the presence of apparently normal or excessive weight
gain.
3.2. Laboratory investigations
A variety of investigations may be helpful in the
assessment of the patient’s nutritional state w42x, such
as haemoglobin, total white cell and neutrophil count,
serum albumin andyor pre-albumin. Urea and electro-
lytes should be checked whenever clinical progress is
not entirely satisfactory to identify salt depletion and
pseudo-Bartter’s syndrome, which may cause significant
growth failure w43x. Besides an ultrasound examination
of the liver and upper abdomen, plasma fat-soluble
vitamin A, D and E levels should be measured annually.
3.3. Definition of malnutrition
Malnutrition is defined as a weight for height value
below 90% in children or as BMI below 18.5 in adults.
4. Factors contributing to malnutrition in CF
4.1. Features of malabsorption in CF patients
Malabsorption is characterised by foul smelling loose
pale stools. Infants identified through newborn screening
exhibit intestinal malabsorption which is of early onset
and severe and if left untreated leads to severe malnu-
trition and growth failure w44x. Newly diagnosed chil-
dren and adults may have untreated malabsorption and
should be evaluated. Due to the progressive nature of
the pancreatic damage, pancreatic sufficient patients w45x
may eventually develop pancreatic insufficiency w46x.
Malabsorption of fat and nitrogen is severe without
enzyme treatment; nonetheless, some 40–50% of ingest-
ed dietary fat is absorbed without treatment. This is
probably due to the action of lingual and gastric lipase
w47x. Carbohydrate malabsorption is minimal w48x. Even
when clinical symptoms appear to be controlled by
pancreatic enzyme supplementation, many patients still
have a significant degree of fat malabsorption. Thus, the
control of gastrointestinal signs and symptoms is not
always indicative that malabsorption is controlled.
Equally, persisting abdominal signs and symptoms in
the face of apparently reasonable doses of enzymes may
not be due to inadequate enzyme treatment but some
other cause such as constipation w39x.
4.1.1. Factors other than enzyme deficiency contributing
to malabsorption
Deficiency of pancreatic enzymes is the most impor-
tant, but not the only factor, responsible for malabsorp-
tion in CF w49x. A further important consequence of the
severe pancreatic damage is deficiency of pancreatic
bicarbonate resulting in diminished capacity to buffer
influxes of gastric acid into the duodenum w50x. This
results in reduced efficacy of endogenous and exogenous
pancreatic enzymes and precipitation of bile salts
w51,52x. Bile salt replacement contains a relative reduc-
tion in taurine-conjugated and an increase in glycine-
conjugated bile salts w53x, the latter being less effective
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at lipid solubilisation. Mucosal ion transport abnormal-
ities resulting from deficiency of intestinal CFTR affect
both water and electrolyte transport w54x. In an acid
medium fatty acids, which are formed by fat digestion
at the oilywater interphase, are not converted into soaps
but occur in the protonated form. In this form, they are
not transferred to the micellar phase but remain in the
oil phase. This may further hamper fat digestion as
under these conditions pancreatic lipase may catalyse
the formation of triglycerides out of their digestion
products. There may also be impaired mucosal uptake
and transport of long chain fatty acids w55x as well as
altered motility with an increase in small bowel transit
time w56x. A variety of structural abnormalities may
result from previous gastrointestinal surgery for meco-
nium ileus including shortened bowel, strictures at the
site of previous intestinal anastomosis, malrotation and
adhesions. In all patients there are histological abnor-
malities of the bowel wall characteristic of CF and an
excess of mucus may also be relevant w57x.
4.1.2. Investigation and diagnosis of malabsorption
It is important to obtain some objective evidence of
both intestinal malabsorption and pancreatic abnormality
in all patients with CF both to identify those who require
enzyme treatment, and to monitor the success of such
treatment. If there is abdominal distension, abdominal
discomfort, loose oily pale stools, and the patient is
malnourished it is most likely that there is intestinal
malabsorption w39,58x. Demonstrating that intestinal
absorption is controlled prevents unnecessary and poten-
tially harmful increases in the enzyme dose and also
prompts a search for another cause for the symptoms
w22x. Poor weight gain and growth, particularly if the
appetite is good, are suggestive of malabsorption. Indi-
rect pancreatic function tests, which detect abnormalities
secondary to loss of pancreatic function, such as mal-
digestion and consequent malabsorption, are generally
employed, because they are easier to perform and less
invasive than direct assessment of the secretory capacity
of the exocrine pancreas
The degree of fat malabsorption is usually taken as
the marker of intestinal malabsorption. The gold stan-
dard for measuring fat absorption is an assessment of
the fat excretion over 3 days and its relation to dietary
fat intake over the same time period. Normally the
equivalent of less than 7% of the fat ingested is excreted
i.e. there is over 93% fat absorption. The total faecal fat
output is usually less than 7 g per day in healthy adults
and less than 2 g in small children w59x. Measurement
of faecal fat using near infrared spectroscopy w60x
compares favourably with the routine titrimetric method
w61x. As a minimum measurement of steatorrhoea, a
semiquantitative estimate of faecal fat content should be
made by a method of faecal microscopy or acid steato-
crit, which have been validated by comparison with
quantitative measurements w62,63x. Other indirect pan-
creatic function tests including the determination of
relatively non-biodegradable pancreatic enzymes in fae-
ces (chymotrypsin w64x and particularly, faecal pancre-
atic elastase 1 w65,66x) and tests which evaluate the
capacity of pancreatic enzymes to cleave specific syn-
thetic substrates (e.g. PABA). The carbon mixed13
triglyceride breath test is a safe non-invasive way of
assessing fat digestion that can be used repeatedly in
children w67x. However, a large inter-individual variation
under condition of relatively mild fat malabsorption has
recently been documented in a rat model, suggesting
that this test, as most other indirect tests of pancreatic
function may be particularly useful for revealing severe
pancreatic insufficiency w68x. The serum concentrations
of specific pancreatic enzymes (immunoreactive trypsin
w69x and lipase) can be used to document residual
pancreatic function.
4.2. Energy expenditure
The main factors leading to energy loss are malab-
sorption due to pancreatic insufficiency and inflamma-
tion. Glucosuria in diabetic patients and protein loss in
large amounts of sputum may contribute to energy
losses. As the energy intake is often lower than the
120–150% of the recommended daily amount, a nega-
tive energy balance is frequently seen in patients with
CF. Energy requirements are determined by measuring
energy expenditure. Approximately 60–70% of total
energy expenditure is determined by resting energy
expenditure (REE), 10–25% by physical activity, and
10% for diet-induced thermogenesis.
Energy expenditure can either be measured or calcu-
lated. Methods for quantifying energy expenditure are:
(1) indirect calorimetry; (2) direct calorimetry; (3) 24-
h energy expenditure with stable isotopes; and (4) the
24-h monitoring of heart rate. Intra-individual variation
of direct or indirect calorimetry is approximately 3%,
while the 24-h techniques have much larger variances
(10–15%). If techniques for measuring energy expen-
diture are unavailable; (5) REE can be estimated from
body size. A direct comparison of these standards and
measured values revealed differences of up to "20% in
healthy individuals. For patients with CF, a specific
formula has been developed which is based on the
FAOyWHOyUNO equation and supplemented with dis-
ease and activity factors w21x. However, when compared
with results from indirect calorimetry, this equation
underestimated REE in children and infants with CF
w70,71x.
Many investigators report on increased REE in
patients with CF w72–78x. This increased REE is not
always associated with an increase in total energy
expenditure, especially in stable patients with moderate
pulmonary disease w79x. With few exceptions, mean
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REE was reported to be increased by 7–35% in patients
with CF compared with predicted values. However, a
large range of values was obtained between different
individuals. Impaired lung function causes a higher
workload for respiratory muscles, and increased oxygen
cost of breathing, causing in CF a REE twice that of
controls w72x. Chronic inflammation may also be asso-
ciated with higher energy expenditure and correlations
with concentrations of TNFa have been reported w77x.
Acute respiratory exacerbations cause an increased REE
in many patients, which reverts to lower values after
antibiotic therapy w74–77x. Similarly, after 2 weeks of
aerosolised dornase alpha, a decline of REE was
observed w78x. Some authors reported correlations with
improvements of FEV , CRP, TNFa, or body weight,1
suggesting a parallel reduction in the host inflammatory
and catabolic responses after treatment.
Patients homozygous for DF were reported in some508
studies to have higher mean REE w80–82x, whereas
other authors did not find such a relation w83,84x.
Therefore, if an energy-requiring defect is present in CF,
its contribution to increased REE must be small. There
is a paucity of data concerning longitudinal follow-up
of individual patients. In the only long-term observa-
tional trial REE was considered as an early indicator of
disease severity independent of pulmonary function w81x.
Beta-agonists are bronchodilators that are frequently
administered in patients with CF. Salbutamol, a major
drug of this class, has been shown to increase resting
energy expenditure by 10% during the first hour after
inhalation w85x. When administering beta-agonists sev-
eral times a day, an effect on energy requirements should
be considered.
4.3. Inadequate energy intake
The poor energy intake of many individuals with CF
has been well documented. Although intakes in excess
of 120% of the estimated average requirement are
commonly advised, when the actual energy intake is
measured it is often considerably less than this w86x,
particularly in male patients w87x.
Additionally, specific muscle stimulation with anabol-
ic medication appears to be an option. In patients with
CF it has been shown that megestrol acetate, a proges-
tagon, leads to an increased appetite, an increase in
bodyweight with an increase in lean body mass and
pulmonary function w88–90x. Disadvantages are the
possible development of diabetes, inhibition of growth
and adrenal suppression w89x. This is a subject which
need further research, and because of the side effects
and the limited data available, patients should only be
treated with anabolic medication in clinical trials.
Growth hormone has also been shown to improve
growth and clinical status in pre-pubertal patients with
CF w91x. Growth hormone therapy is also associated
with a number of side effect e.g. glucose intolerance.
Further research is required before its use can be widely
accepted in the clinical situation.
4.4. Liver disease and bile salt loss
A significant percentage of individuals with CF even-
tually have biochemical, ultrasound or clinical evidence
of liver disease. Prevalence estimates of liver involve-
ment in CF remain highly variable; ranging between 2%
and 37% among the studies based on the largest CF
series. On the other hand three prospective studies
recently carried out indicate that liver disease is a
relative frequent and early complication of CF. Preva-
lence of cirrhosis is approximately 10% w92,93x. In one
third of these patients liver disease develops before the
age of 5 years. Patients with CF who have overt clinical
liver disease commonly have serious nutritional prob-
lems both generally and also relating to specific mac-
ronutrients, fat-soluble vitamins and clotting factors
w94x. Many patients with CF have increased losses of
bile salts in the intestine w52x. Bile salt deficiency
compromises lipolysis leading to a reduction in fat
absorption of up to 50%. In one study lipolysis of the
substrate was not affected in patients with CF related
liver disease using the C-mixed triacylglycerol breath13
test w95x, but, bile salt concentration or intestinal loss
was not studied. Ursodeoxycholic acid (URSO) is
accepted as a treatment for biochemical liver disease
and has a beneficial effect on liver enzyme levels.
Whether treatment with URSO leads to an improvement
in nutritional state is unknown. Studies that show long-
term effects on the prevention of fibrosis are lacking,
and the observation that the nutritional state of patients
with CF and liver disease improved with URSO w96x
was not confirmed in a controlled trial w97x. Liver
transplantation in such patients, however, has a benefi-
cial effect on their nutritional state w98x.
4.5. Diabetes mellitus
Estimates of prevalence of CF related diabetes melli-
tus (CFRD) vary from 2.5% to 12% of patients, increas-
ing considerably with age. In Denmark, 32% of patients
with CF developed diabetes mellitus by the age of 25
years w99x. This obviously has considerable nutritional
significance. CF related diabetes mellitus shares features
of both type 1 and type 2 diabetes but is a distinct
clinical entity. The primary cause is insulin deficiency
but it is also influenced by unique CF conditions.
Undernutrition, chronic and acute infection, elevated
energy expenditure, glucagon deficiency, malabsorption,
abnormal intestinal transit time, bacterial overgrowth,
and liver dysfunction all influence glucose tolerance.
The diagnostic criteria of (CFRD) are reported in a
recent consensus report of the US CF Foundation w100x:
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(i) 2-h plasma glucose (PG) )11 mmolyl during a 75-
g OGTT; (ii) fasting PG (FPG) )7.0 mmolyl on two
or more occasions; (iii) FPG )7.0 mmolyl plus casual
glucose level )11.1 mmolyl regardless time or last
meal; and (iv) casual glucose levels )11.1 mmolyl on
two or more occasions with symptoms. The HbA1c
screening should not be used for detection of new cases
of CF related diabetes mellitus but only for monitoring
the degree of control of blood glucose levels in patients
with established CFRD. The management of CFRD is
beyond the scope of the present consensus on nutrition.
5. Essential fatty acid (EFA) deficiency
Patients with CF carry a high risk of low essential
fatty acid levels, which have often been considered as
essential fatty acid deficiency. Plasma and tissue lipids
of patients with CF tend to have low contents of the
precursor EFA, linoleic and a-linolenic acids w101,102x.
Several studies have also reported reduced levels of
omega-3 long-chain polyunsaturated fatty acids (LC-
PUFA), such as eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA) w103x. In contrast,
controversial data exist for omega-6 LC-PUFA, such as
arachidonic acid (AA), which may be normal, reduced
or even increased w103x. A disturbed EFA and LC-PUFA
status has been related to a variety of physiological
impairments and adverse effects, such as altered
membrane and cellular functions, skin lesions, alteration
of immune, renal, hepatic and pulmonary functions
w104,105x. Many of these symptoms are also observed
in animals with experimental EFA deficiency w106x.
However, the question of possible causality in patients
with CF requires further clarification.
Proposed mechanisms that can lead to polyunsaturated
fatty acid depletion in patients with CF include maldi-
gestion and malabsorption of dietary lipids, as well as
underweight and negative energy balance with an
increased beta-oxidation of polyunsaturated fatty acids.
Moreover, enhanced peroxidative destruction of poly-
unsaturated fatty acids in patients with poor antioxidant
status and high oxidative stress induced by infections
may contribute to low polyunsaturated fatty acid con-
centrations. Alterations of EFA conversion to LC-PUFA
which were proposed to be either causally linked to the
basic defect in CF or secondary to disease related
physiological alterations, an increased turnover of lino-
leic acid w107x and an increased release of arachidonic
acid (AA) from phospholipids w108x have been proposed
but require further clarification. It is also of interest that
in a controlled trial, URSO therapy for 6 months led to
an improvement of the EFA status w109x.
6. Vitamin deficiency
6.1. Vitamin A
Low serum vitamin A concentrations are frequent in
untreated patients with CF, regardless of age, nutritional
status, meconium ileus, Shwachman score, genotype and
exocrine pancreatic function w110x. Pancreatic enzyme
replacement to correct steatorrhoea apparently fails to
normalise serum vitamin A concentrations. The occur-
rence of biochemical deficiency in patients without
steatorrhoea, suggests that other mechanisms, such as a
disturbance in mobilisation of hepatic stores, are
involved. A positive correlation between retinol binding
protein (RBP) concentrations and zinc status has been
demonstrated w111x. Studies currently available trying
to clarify the interrelationship between vitamin A status
and liver disease are inconclusive. In a recent study
hepatic vitamin A stores in CF were found to be lower
than normal, they decreased with age and showed no
correlation to the severity of CF related liver disease
w112x.
Many studies of vitamin A in CF underline the poor
correlation between biochemical and clinical findings.
However, patients with CF with decreased serum retinol
concentrations were found to have disturbed dark adap-
tation, which was reversed by supplementing vitamin A
w113x. Morphological changes of the eye like xerosis,
have been reported recently but are exceptional w114x.
Low vitamin A levels are associated with poorer clinical
status w115x and impaired lung function w116x. Whether
this is related to the role of vitamin A in the immune
system or any other specific function is unclear. Plasma
levels of b-carotene that acts as an antioxidant on its
own are low in practically all pancreatic insufficient
patients with CF.
6.2. Vitamin D
A quarter of infants with CF detected in a newborn
screening program were shown to have decreased serum
concentrations of 25-OH-cholecalciferol in the first 3
months of life, before any treatment was started w117x.
This finding could be explained by the low serum levels
of the vitamin D-binding protein in CF homozygotes,
suggesting that in CF hypovitaminosis D is mainly a
transport problem w118x. Sunlight is the major determi-
nant of the amount of vitamin D in the body, which
mainly depends on seasonal variation, geographical
location and skin pigmentation. When there is sufficient
skin exposure to ultraviolet light, dietary supplementa-
tion is not essential. As result it is very difficult to
establish normal serum values and the frequency of
deficiency in different studies varies accordingly w119x.
For vitamin D decreased biochemical concentrations
have also been found much more frequently than clinical
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deficiency states such as rickets. In adolescents and
adults osteopenia and osteoporosis are well documented
but decreased vitamin D concentrations only play a
minor part w119,120x.
There are anecdotal reports of severe clinical defi-
ciency states in heavily pigmented adolescents living in
northern regions, after darker winter months.
6.3. Vitamin E
a-Tocopherol is a powerful antioxidant protecting
lipoproteins and cellular membranes against destruction.
Oxidative stress is enhanced in patients with CF due to
chronic respiratory inflammation w121x. Almost all new-
ly diagnosed patients with CF have low vitamin E
plasma concentrations irrespective of exocrine pancreatic
function w110x. This and the fact that administration of
pancreatic enzymes does not correct an existing bio-
chemical vitamin E deficiency suggests that exocrine
pancreatic insufficiency is not the only underlying path-
ogenetic mechanism. Impaired intestinal availability of
bile acids plays an equal or even more important role
in vitamin E uptake from the gut w122,123x. CF related
liver disease with only mild cholestasis does not seem
to play a significant role in this context w124x. Vitamin
E absorption is also improved by URSO w124x
Although biochemical vitamin E deficiency is a fre-
quent finding in patients with CF, clinical symptoms are
a rare event. However, long-standing severe biochemical
deficiency will eventually result in irreversible neurolog-
ical damage. Therefore, routine testing for biochemical
vitamin E deficiency is recommended. A consequence
of biochemical vitamin E deficiency is an impairment
of the resistance of plasma lipids to oxidation w125x. In
infants with CF, clinical deficiency mainly presents as
haemolytic anaemia while in older patients symptoms
are related to the nervous system w126,127x. In one
study abnormal brainstem evoked auditory potentials
were detected and proposed as useful in the evaluation
w128x. No abnormalities, however, were detected in
nerve conduction w129x. Whether vitamin E supplemen-
tation protects against oxidative lung damage in patients
with CF is still speculative. A positive correlation
between percent FEV and plasma vitamin E levels in1
patients with CF was recently reported w130x.
6.4. Vitamin K
As long as vitamin K was only supposed to be
important in coagulation, a diagnosis of deficiency was
exceptional and supplements were restricted to patients
with haemoptysis, uncontrollable malabsorption from
pancreatic disease, liver disease, intestinal resections or
long-term use of antibiotics w131x. Recent studies indi-
cate vitamin K acts as a cofactor in the carboxylation,
not only of prothrombin involved in coagulation, but
also of osteocalcin in bone formation w132x. Determi-
nation of proteins induced in vitamin K absence (PIV-
KA), a new sensitive method for the measurement of
this vitamin, demonstrates that deficiency is common in
CF especially in unsupplemented pancreatic insufficien-
cy w133x. Based on the carboxylation state of these
proteins in patients with CF, 5 mg vitamin K was
supplemented weekly without reaching normal levels in
these patients w134x. But in a recent study from Toronto
unsuspected biochemical vitamin K deficiency was part-
ly corrected by an oral supplement w135x. A water-
soluble, oral vitamin K preparation is often given to
patients with CF, even though adequate comparative
data on the bioavailability of vitamin K from the
standard preparation and the water-soluble micellar prep-
aration are unavailable. The parenteral route should only
be chosen to correct an acute symptomatic deficiency,
in severe liver disease or malabsorption. Further studies
are needed in patients with CF with liver disease, severe
malabsorption, small bowel resections and long-term
antibiotic use before the optimal dose of vitamin K is
determined.
6.5. Water soluble vitamins
Water-soluble vitamins usually do not pose an appre-
ciable problem in CF. Many patients with CF with
exocrine pancreatic insufficiency have a disturbed Schil-
ling test indicating an abnormal vitamin B12 absorption,
but pancreatic enzyme preparations promote absorption
of vitamin B12. Patients who underwent extensive resec-
tions of the terminal ileum need lifelong treatment with
a parenteral administration of 100 mg vitamin B12 per
month. In contrast, vitamin B12 deficiency in pancreatic
sufficient patients with CF not taking pancreatic enzyme
supplements is exceptional w136x. Plasma vitamin C
concentrations are inversely related to age and different
indices of inflammation w137x. The antioxidant role of
vitamin C is currently under investigation.
7. Mineral and trace element deficiency
In the daily diet, macronutrients are needed for the
body in relative large amounts and are important for the
cell or the extracellular compartment. Micronutrients as
cofactors are essential for enzymatic reactions or as
structural elements of proteins.
7.1. Minerals
Sodium and chloride are the most important ions in
the extracellular fluid w138x. The mean daily intake of
sodium is between 6 and 9 g a day for adults, which is
in excess of the daily minimal requirement (-3.5 gy
day). Newborns need more sodium and chloride in
relation to their bodyweight for the increase of extra
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Table 2
Minimal daily requirements for sodium, chloride and potassium in
normal individuals
Age Sodium Chloride Potassium
(mg) (mg) (mg)
-1 year 120–200 180–300 500–700
)1 year 225–500 350–750 1000–2000
Source: National Research Council, 1989. In CF more loss through
sweat and stool can be anticipated, and has to be supplemented on an
individual basis.
cellular volume. The minimal need is based on the
concentration of breast milk (sodium 160 mgyl, chloride
385 mgyl, and potassium 500 mgyl). In the first 6
months the population reference intake (PRI) for sodium
is 23 mgykg per day, the recommended intake is 23–
46 mgykg per day. For newborn babies the acceptable
intake for chloride is 35–71 mgykg per day. The daily
sodium loss in sweat is approximately 500 mg in adults.
The loss may increase 10 times in CF during exercise
in the sun, sometimes accompanied by hyponatraemia
and alkalosis. In moderate climates the excess of sodium
intake in food compensates this extra loss. The serum
sodium concentration is regulated by the renin-angioten-
sin-aldosterone axis that diminishes the sodium excretion
in the urine during activation. In most patients this
balance is maintained. Since human milk is low in
sodium, breast fed babies may need supplementation
during fever or hot summer months.
Potassium is the most important intracellular cation,
involved in nerve conductance, muscle contraction and
blood pressure. Potassium loss with sweat is low. The
mean potassium intake for adults is between 2 and 3.5
g daily. Rapidly growing young children need during
increased growth velocity approximately 78 mgy100
kcal (recommended intake) or 35–78 mgykg per day
(acceptable intake) (Table 2).
Calcium is important for the mineralisation of the
skeleton, muscle contractions and signal transmission in
the nervous system w139x. Fat malabsorption and vitamin
D deficiency are the main causes of low calcium uptake
in the intestine w140x. Calcium intake in non-CF indi-
viduals is dependent on age and growth velocity. Chil-
dren need 400 to 800 mg calcium and adolescents 800–
1200 mg calcium daily. In CF, tetany, rickets or clotting
abnormalities are rare. Plasma calcium levels and calci-
um excretion in the urine are normal. In young children
with CF bone mineralisation is thought to be normal,
but in adolescent and adult patients with CF bone
mineral density and bone content is often diminished
and spontaneous fractures are described w141x. Also
phosphate homeostasis is strongly related to calcium
and regulated by vitamin D w142x. Most food products
are rich in phosphate and a deficient intake is excep-
tionally rare. Only young infants with low body weight
are at risk for nutritional deficiency of phosphate. The
ideal ratio of calcium to phosphate intake is 2:1.
Only 1% of the body store of magnesium (adult: 25
g) is in the extracellular fluid. Magnesium is important
in the skeleton (60% of the magnesium pool) and
muscles and in many biochemical processes. Normal
serum levels are 0.7–1.0 mmolyl. Based on the concen-
tration in human milk the recommended dose for infants
and young children is 7 mgykg per day and for adults
3.5 mgykg per day. Hypomagnesaemia is characterised
by tremor, tetany, neuromuscular irritability and seizures.
Magnesium absorption is disturbed in pancreatic insuf-
ficiency and is closely associated with calcium and
phosphorus. Urinary magnesium excretion is increased
by aminoglycosides probably causing renal tubular dam-
age w143x. Serum levels do not always correlate with
the severity of symptoms.
7.2. Trace elements
The iron store in the body is 3–4 g of which 70% is
in the red blood cells and 25% in ferritin and haemosi-
derin in liver, spleen and bone marrow. The transport
protein in plasma is transferrin. Children need 5–10 mg
of iron daily. Iron deficiency is frequent in CF and
caused by multiple factors: inadequate dietary intake,
malabsorption, chronic infection, and blood loss. Pan-
creatic enzymes may be responsible for impaired oral
iron absorption and iron should not be supplemented in
close proximity to pancreatic enzyme supplements w144x.
It is unclear whether iron supplementation will improve
the iron status, which is monitored by measuring serum
ferritin levels in patients with CF. Ferritin levels can be
increased during infection.
The total body zinc content is 2 g and most of it is
intracellularly deposited in the skeleton, muscles, liver
and skin. Red blood cells contain 0.9–1.5 mg zinc per
100 ml. Zinc has an important function in many
enzymes. Deficiency is characterised by growth retar-
dation, acrodermatitis, and disturbed immune function.
Children need 5–10 mgyday and adults up to 15 mg. It
is suspected that subclinical zinc deficiency due to fat
malabsorption is wide spread in CF and is caused by
zinc forming complexes with fat and phosphorus w145x.
Pancreatic enzyme supplements improve zinc absorption
w146x.
Like zinc, copper is part of many enzymes and found
mostly intracellularly in liver, muscle and bone. In the
plasma copper is bound by caeruloplasmin. Copper
deficiency results in anaemia, neutropenia, heart disor-
ders, muscle weakness, immune disorders, pancreatic
atrophy, and connective tissue impairment. Copper defi-
ciency is only partially represented by plasma copper
levels because caeruloplasmin is an acute phase protein.
There is insufficient information to support supplemen-
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tation of copper more than the age appropriate recom-
mended daily allowance (RDA) w147x.
Selenium is an essential part of the antioxidant glu-
tathione peroxidase. Deficiency of selenium causes car-
diomyopathy and muscle weakness. Glutathione
peroxidase activity in red blood cells is a better indicator
of selenium status than plasma values. In CF there is an
indication that the selenium status is disturbed w148x,
however, at present, it cannot be recommended to
supplement selenium in patients with CF. Pancreatic
enzyme preparations contain 0.5–1.6 mgyg of selenium
and this amount is sufficient to affect glutathione per-
oxidase activity w149x.
Iodine is incorporated in hormones of the thyroid
gland. Iodine deficiency does not occur in CF, since
iodine is easily absorbed from food. Iodine requirements
increase with age: 40 mg during the first 6 months to
150 mg at 10 years. Manganese is necessary for the
antioxidant superoxide dismutase. The total body pool
is 10–20 mg and supplementation for patients with CF
is not needed. Similarly, molybdenum deficiency is
extremely rare and does not need supplementation.
Chromium plays a role in carbohydrate and lipid metab-
olism and protein synthesis and is important for growth.
Patients with CF had normal plasma levels during
supplementation of 0.5–0.75 mgykg per day w150x. It is
questionable if supplementation is necessary. Fluorine is
found in tooth and bone and supplements are not
required.
8. Antioxidant deficiency
In patients with CF, the antioxidant protective screen
is markedly disturbed as a result of impaired status of
glutathione, vitamin E and carotenoids such as b-
carotene and lycopene. Occasionally low plasma con-
centrations of albumin, vitamin C and selenium are
found. Glutathione deficiency has been described to
occur both locally in the CF airways and systemically
w151x. Glutathione is transported via the CFTR, sug-
gesting that glutathione deficiency is intrinsically related
to CF w152x. The glutathione status is also associated
with nutritional status w153x. Carotenoids are highly
lipophilic compounds not considered to be vitamins, of
which the plasma and lipoprotein concentrations are
very low in CF patients with exocrine pancreatic insuf-
ficiency. In addition to its provitamin A function, b-
carotene acts as an antioxidant. Correction of poor
vitamin E and b-carotene status to normal enhances the
resistance against oxidation of plasma lipoproteins
w125,154x, decreases plasma lipid peroxidation w154–
156x and reduces inflammation w157x. For counterbal-
ancing the enhanced reactive oxygen species production
due to chronic inflammation, full correction of the
antioxidant screen is warranted. Future studies should
address the question as to whether the final goal of
antioxidant supplementation is to achieve plasma con-
centrations in CF higher than those in healthy subjects.
9. Prevention of malnutrition and treatment of pan-
creatic insufficiency
Prevention of malnutrition requires early intervention.
Therefore early diagnosis is of importance and may be
achieved by neonatal screening w9x. Following diagnosis,
frequent reviews by a specialist CF dietician are man-
datory; during the first 12 months after diagnosis at
least once every month, thereafter at least every 3
months. The frequency of clinical reviews depends on
the clinical state, control of the malabsorption and
weight gain. Patients on a special diet (e.g. vegetarian)
should be monitored more closely.
The majority of individuals with CF can tolerate a
normal to high fat diet if treated with pancreatic enzymes
in doses (Tables 3 and 4) matched to fat intake w158x.
A 3-day faecal fat study and dietary assessment is the
best measure of fat absorption. The diet is quite often
low in fibre but for some who experience recurrent
abdominal pain, an increase in fibre intake to 30 g per
day with additional water may reduce abdominal symp-
toms w159x and may lead to an improved appetite and
energy intake in some patients. In children with CF and
well-controlled absorption and only mild chest infec-
tions, a normal energy intake may be sufficient. How-
ever, if the nutritional state andyor growth are abnormal,
the diet should provide in excess of 20% of the recom-
mended daily amount and high-energy dietary supple-
ments or even enteral tube feeding may be required. As
energy requirements vary so widely it is important that
an assessment of each individual’s needs is undertaken.
9.1. Infant feeding
Infants with CF fed on breast milk w5x achieve normal
weight gain and growth by the age of 1 year as do
infants on normal formulae w6x and those fed on a
predigested medium chain triglyceride containing for-
mula w160x. For the first year of life the ESPGHAN
recommendation of exclusive breast feeding for the first
4–6 months of life is appropriate for the infant with CF.
w5x. If breast-feeding is not possible or there is insuffi-
cient milk, cows’ milk-based infant formulae can be
used w6,160x. Whole cows’ milk should not be given
during the first year of life. Infants who receive a feed
containing adequate energy and who are also given an
appropriate dose of supplemental pancreatic enzymes
should thrive satisfactorily irrespective of the type of
milk w6,161x. Extensively hydrolysed protein formulae
should be considered for infants who have undergone
extensive gut resection for meconium ileus and for those
with milk intolerance (e.g. cows’ milk allergy or lactose
intolerance) w162x. A feed containing medium chain
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Table 3
Minimum enzyme content of pancreatic enzyme preparations
Name Maker Lipase Protease Amylase
Enteric-coated microspheres
Cotazym Thiemann
10 000 10 000 Ph Eur u 375 Ph Eur u 6250 Ph Eur u
20 000 20 000 Ph Eur u 750 Ph Eur u 12 500 Ph Eur u
30 000 30 000 Ph Eur u 1125 Ph Eur u 18 750 Ph Eur u
40 000 40 000 Ph Eur u 1500 Ph Eur u 25 000 Ph Eur u
Nutrizym GRa Merck 10 000 BP u 650 BP u 10 000 BP u
Pancrease Janssen-Cilag 5000 BP u 330 BP u 2900 BP u
Enteric-coated minimicrospheres
Creon Solvay
10 000 10 000 Ph Eur u 600 Ph Eur u 8000 Ph Eur u
25 000 25 000 Ph Eur u 1000 Ph Eur u 18 000 Ph Eur u
40 000 40 000 Ph Eur u 2000 Ph Eur u 30 000 Ph Eur u
For children 5000 Ph Eur u 200 Ph Eur u 3600 Ph Eur u
Enteric-coated minitablets
Nutrizyma Merck
10 10 000 BP u 500 BP u 9000 BP u
22 22 000 BP u 1100 BP u 19 800 BP u
Panzytrata Knoll
10 000 10 000 Ph Eur u 500 Ph Eur u 9000 Ph Eur u
25 000 25 000 Ph Eur u 1250 Ph Eur u 22 500 Ph Eur u
Pancrease HLa Janssen-Cilag 25 000 BP u 1250 BP u 22 500 BP u
Note: For amylase and lipase 1 BP units1 Ph Eur unit; for protease there is no direct equivalence between BP and Ph Eur units because of
the use of different assay methods.
Eudragit-coated.a
triglycerides should be considered in patients with cho-
lestasis or uncontrolled steatorrhoea. If weight gain is
poor, additional energy supplements may be added to
formulae or a high-energy infant formula used. A normal
to high fat weaning diet is recommended depending on
the infant’s growth. The first 2 years are a period of
very rapid growth; therefore close monitoring of the
general condition, the nutritional state and the growth
rate of the infant with CF is needed. If poor weight gain
is related to an increase in frequency of chest infections,
vigorous treatment of the latter will both improve the
nutritional state and reduce the amount of pulmonary
damage.
Treatment of acute and chronic lung infection nor-
mally results in an increase in bodyweight, which is
related to a reduction in systemic inflammation w163–
166x.
9.2. Control of malabsorption achieved with current
enzymes preparations
Enzyme preparations may differ in their enzyme
content, which often varies with batches, in their disso-
lution characteristics in relation to the pH and to other
constituents of the duodenal fluid w167x and in the size
of the particles and their rate of exit from the stomach
in relation to the meal. The practical details of admin-
istration, including adjusting the enzyme dose to the fat
intake and the timing in relation to the meal will have
a significant effect. Future studies are needed in this
context.
Coefficients of fat absorption of between 85% and
95% of intake should be possible with presently avail-
able enzyme preparations w168–173x. Nevertheless, a
substantial number of patients with CF do not achieve
normal absorption w174x. Based on reports of fibrosing
colonopathy, various guidelines for the use of pancreatic
enzymes in CF have appeared w58,175–177x. Recom-
mendations are summarised in Table 4.
9.3. Failure to control gastrointestinal symptoms
Sometimes, control of symptoms is not achieved even
with a dose of enzyme equivalent to the recommended
10 000 IU lipaseykg per day w175x is given in an
appropriate manner. The degree of residual malabsorp-
tion should be estimated and other gastrointestinal dis-
orders should be considered. A progressive increase in
enzyme dose without further investigations is not rec-
ommended w178x. Distal intestinal obstruction syndrome
(DIOS) is characterised by recurrent attacks of abdom-
inal pain with variable symptoms of obstruction and is
relatively common in patients with CF w179x. An
increase in pancreatic enzyme dose in patients with
DIOS is likely to worsen the abdominal pain and
constipation w22x. Other possible gastrointestinal prob-
lems include gastro-oesophageal reflux, which seems to
be common both in infants w180,181x and older patients
62 M. Sinaasappel et al. / Journal of Cystic Fibrosis 1 (2002) 51–75
Table 4
Recommendations for pancreatic enzyme supplementation therapy in CF
Infants
• Use a microsphere or minimicrosphere preparation
• For every 120 ml infant formula or breast milk give as the initial dose of
one-quarter to one-third of a capsule of standard strength pancreatin (as
Creon 10 000s2500–3333 IU lipase; as Pancreases1666–2500 IU lipase).
These doses equate to approximately 400–800 IU lipase per g of dietary fat.
• Mix the enzyme microspheres or minimicrospheres with a small amount of
infant formula or expressed breast milk or fruit puree and give from a spoon
directly before the feed.
• Increase the dose gradually according to clinical symptoms, appearance of
the stools and objective assessment of weight gain, growth and absorption.
• Once solid food is introduced, individually titrate enzyme dose according to
the fat intake. Regular advice from a dietician is mandatory for best results.
• Aim to keep the lipase intake below 10 000 IU per kg body weight per day.
Older children and adults
• Initial dose of 1–2 capsules of standard pancreatin preparation (as Creon
10 000s10 000-20 000 IU lipase; as Pancreases5000–10 000 IU lipase)
per meal and a half to one capsule with fat containing snacks.
• One paediatric unit has continued to use high strength microsphere capsules
(Creon 25 000) without problems.
• Enzymes should be given with all fat containing foods and supplements.
The dose should be worked out individually, initially with the help of a
dietician, and varied according to the fat intake. Dose requirements can
vary widely between 500 and 4000 IU lipase per gram of dietary fat.
• The capsules should be swallowed whole at as early an age as possible and
many children will manage this by 3 or 4 years, some very much earlier. If
removed from the capsules, the microspheres should not be sprinkled on or
mixed with the whole meal but should be mixed with a little fluid or food
and immediately given from a spoon in one swallow. They should not be
crushed or chewed.
• Enzymes are best given at the beginning or early in the meal, e.g. half the
dose at the beginning and half in the middle of the meal.
• The dose is gradually increased until the symptoms are controlled when
evidence is sought that absorption has been controlled.
• Patients and parents should be encouraged to discuss any problems they
may have with adherence to enzyme treatment.
• In tube or gastrostomy fed patients pancreatic enzymes should be given
before and after the feed.
From: Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis. Paediatr Drugs 2000;2:205–222.
w182x, inflammatory bowel disease w183x, pancreatitis in
pancreatic sufficient patients w184x, short bowel with
bacterial overgrowth and adhesions after intestinal sur-
gery, liver and gall bladder disease w185x, cows’ milk
protein allergy or lactose maldigestion w162x and even
intolerance to the porcine enzyme preparations w186x.
Patient adherence to treatment provides another prob-
lem in the control of gastrointestinal symptoms and the
role of an experienced dietician to discuss the practical
details of treatment in such circumstances cannot be
over emphasised.
Reduction of gastric acid has improved absorption in
patients with CF where control was poor even with
enteric-coated acid resistant enzymes. Treatments have
included cimetidine w187x; ranitidine w188x omeprazole
w189x and lansoprazole w190x Long-term side effects of
this group of drugs have not been investigated. Taurine-
conjugated bile acids are in relatively short supply due
to the gastrointestinal losses, which occur in CF. There
is a relatively greater compensatory production of gly-
cine-conjugated bile acids w52x. Therefore, in CF taurine-
conjugated bile acids, which are more efficient at lipid
solubilisation, are deficient in plasma and bile w53x.
There is still controversy as to whether or not oral
taurine corrects the deficiency and improves the malab-
sorption. Further studies are needed w191x.
10. Side effects of pancreatic enzymes
Hyperuricaemia and hyperuricosuria, which occurred
with the older less pure pancreatic extracts, are no
longer a problem with the modern microsphere prepa-
rations w192x. Soreness of the mouth may occur with
powdered preparations or if acid resistant microspheres
are chewed or held in the mouth and dissolve with a
pH of greater than 5.5. If older powdered preparations
are used in breast-fed infants, soreness both of the
infant’s mouth and of the mother’s nipples may occur.
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Perianal irritation may result from the passage of signif-
icant enzyme activity in the stools if intestinal transit is
rapid or the enzyme dose excessive. The porcine origin
of the pancreatic enzymes causes apparently insignifi-
cant immunological response in most patients w193x,
however, this has been suggested a possible aetiological
factor in fibrosing colonopathy (FC) w194x. Severe acute
and chronic gastrointestinal allergic reactions w186x and
general allergic reactions may occur in people adminis-
tering powdered enzymes to infants with CF w195,196x.
In patients who have had chronic significant fat malab-
sorption a too rapid increase in enzyme dose may cause
severe constipation.
Fibrosing colonopathy (FC) was first reported in 1994
w197,198x. The exact pathophysiology is still uncertain,
however, the progressive increase in pancreatin dose
prescribed for persisting intestinal symptoms appears to
have been a major factor in reaching the very high doses
implicated in FC w198,199x. Toxicity from the co-
polymer Eudragit L30 D55, an acrylic resin based on
polymethacrylic acid and polyacrylic acid esters, used
as an enteric coating by some pancreatin preparations,
has also been proposed w198,200,201x. However, acrylic
resin is widely used in many different preparations and
toxicity the role in the causation of FC is not generally
accepted w202–204x. A list of co-polymer coated prep-
arations is given in Table 3, together with phthalate-
coated alternatives.
With the increased awareness of FC, pancreatin dos-
ing has become more conservative with the recommen-
dation not exceeding 10 000 USP lipaseykg per day;
this and restriction of high strength preparations
()25 000 IU lipaseycapsule) to adult populations has
resulted in a dramatic fall in the incidence of FC in
Europe.
11. EFA treatment
Dietary treatment of patients with CF should aim at
avoiding clearly subnormal levels of EFA and LC-PUFA.
Strategies to achieve that goal include an adequate
supply of energy, polyunsaturated fatty acids of both the
n-6 and the n-3 series in balanced proportions, as well
as antioxidants. Several studies have failed to demon-
strate any general improvement by supplementation of
EFA w205,206x but physiological improvement in liver
steatosis, kidney function and sodium transport have
been reported w207,208x. However, excessive intakes of
EFA and LC-PUFA carry the risk of adverse effects,
such as enhanced lipid peroxidation and unbalanced
synthesis of specific eicosanoids, with clinical
consequences.
Beneficial effects of supplying increased intakes of
specific fatty acids, or groups of fatty acids, have been
proposed. High supplies of fish oil rich in the omega-3
fatty acid EPA reduce the liberation of proinflammatory
leukotrienes from granulocytes of patients with CF in
vitro w209x and in vivo w210x and were reported to
improve pulmonary function in some preliminary studies
w211,212x, this observation deserves further evaluation.
Very high intakes of the omega-3 fatty acid DHA have
been reported to reduce organ damage in a mouse model
of CF. Whether or not comparable clinical benefits can
be achieved in patients with CF supplemented with high
doses of DHA should be evaluated. Based on the
available evidence it is recommended that patients with
CF should receive an adequate dietary intake of omega-
3 fatty acids as is recommended for the general popu-
lation, it is considered premature to recommend high
pharmacological doses of specific omega-3 fatty acids
prior to further characterisation of the efficacy of such
intervention. In a controlled trial, URSO therapy for 6
months led to an improvement in EFA status w109x.
12. Vitamin supplementation
Clinical evidence of vitamin deficiency is rare and
there is no uniformity on the goals of supplementation.
Relevant questions are how to prevent isolated biochem-
ical deficiencies and subclinical abnormalities. The pres-
ent consensus favours prophylactic substitution of those
vitamins for which low blood levels or deficiencies have
ever been described. The initial dose proposed usually
is adequate to normalise blood concentrations in most
patients with CF without causing hypervitaminosis. It is
prudent to measure vitamin blood levels after a few
months and after any change in the treatment of the
malabsorption because this can influence vitamin
absorption. Subsequent supplementation should be
adjusted according to the patient’s blood levels; after-
wards annual monitoring is sufficient w117x.
12.1. Vitamin A
The vitamin A intake should be high enough to
achieve serum concentrations in the normal range with-
out provoking side effects. This can be achieved with
daily doses between 4000 and 10 000 IU of a fat-soluble
preparation w114x. Water-soluble or water-miscible forms
of vitamin A preparations have not been studied in CF.
As absorption and metabolism of vitamin A differ
between individuals, serum concentrations should be
estimated at least once a year and 3–6 months after any
change in dose. If plasma levels are low despite supple-
mentation to the above levels consideration should be
given to patient compliance and the RBP and the zinc
level should be checked. In view of the potential toxicity
of vitamin A, supplementation should never exceed
20 000 IU if the RBP is low. Special consideration must
be given to vitamin A supplementation during pregnan-
cy. A relationship has been suggested between the
incidence of birth defects and high vitamin A intake
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()10 000 IUyday). In CF serum levels should be
checked at the start of pregnancy. If plasma levels are
high it is recommended the dose is reduced. If levels
are low or normal supplementation should continue at a
level less than 10 000 IUyday.
12.2. B-Carotene
In patients with CF with pancreatic insufficiency a
daily dose of 0.5–1 mgykg b-carotene corrected very
low plasma and lipoprotein concentrations to normal
w156–158x. However, plasma concentrations need to be
monitored to make sure that above normal concentra-
tions will not be achieved in the individual patient,
given the fact that in smokers, a group of subjects also
exhibiting oxidative stress, higher than normal plasma
b-carotene concentrations were associated with serious
side effects.
12.3. Vitamin D
As sunlight is the major source of vitamin D for the
body, serum concentrations will depend largely on
endogenous production in the skin and this will differ
between individuals w213x.
Decreased serum concentrations of 25-OH-CC have
been described in patients with CF receiving daily oral
supplementation of up to 2000 IU of vitamin D w214x.
No cases of hypervitaminosis D were reported with this
concentration in patients with CF. No studies are avail-
able on the effect of intermittent large doses. To keep
blood levels within a normal range, a daily dose of
between 400 and 2000 IU is required. Recent evidence
suggests that the serum level should be maintained
within the upper part of the normal range to ensure
optimal bone health w214x. In severe hepatocellular
disease 25-hydroxylation is impaired and therefore 25-
OH-vitamin D is preferred for supplementation w214x.
12.4. Vitamin E
Clinical deficiency states are exceptional in patients
with CF w130x, but enhanced susceptibility to lipid
peroxidation has been demonstrated to occur in patients
with low vitamin E status w126x. Therefore regular
vitamin E supplementation is recommended. As vitamin
E is non-toxic there is no objection to using up to 400
IU daily (s400 mg all-rac-a-tocopheryl acetates450
mg dl-a-tocopheryl acetate or 268 mg RRR-a-tocoph-
erol) w124x. In animals and humans side effects were
only seen when excessively high amounts were given.
The more expensive water-soluble form has no advan-
tage over the fat-soluble form, provided the latter is
taken with pancreatic enzymes w124,215x. RRR-a-
tocopherol and all-rac-a-tocopheryl acetate were shown
to be equally effective, when given at a dose of 400 mg
IUyday w124x. With that dose a normal resistance to
oxidation of lipoprotein could be achieved w126x. It has
been recommended to use for the interpretation of
adequate levels of the plasma, tocopherolytotal lipid or
cholesterol ratio as an index of vitamin E status partic-
ularly when levels are low, because the vitamin E levels
rise with lipids.
12.5. Vitamin K
Routine supplementation with vitamin K has always
been controversial. But recent studies have revealed
unsuspected biochemical deficiency, which may be an
important factor in the osteoporosis in CF w134x. Patients
with demonstrated or suspected deficiency should be
given 10 mg daily. However, the dose required to correct
PIVKA levels is still controversial. A recent randomised
prospective study found better biochemical parameters
with a supplementation of 5 mg weekly w134x. Even
then normal levels were not achieved in all patients
w135x. Probably better results are achieved with a daily
supplement w136x. For systemic substitution, an oral
water-soluble form should be given; parenteral admin-
istration should be reserved for correction of acute
symptomatic deficiency, in severe hepatocellular disease
or uncorrectable malabsorption.
12.6. Water-soluble vitamins
Patients who underwent extensive resections of the
terminal ileum need lifelong treatment with parenteral
administration of 100 mg vitamin B per month. A12
supplement of at least 100 mg vitamin C per day should
be prescribed for patients with an unbalanced diet,
deficient in vitamin C. No other water-soluble vitamin
supplements are needed.
12.7. Conclusion
The doses proposed in Table 5 are those reported to
achieve normal plasma concentrations in patients with
CF without liver disease that will not cause toxicity.
The availability of a preparation that combines the
vitamins at the required doses could help improve
compliance and make life of patients with CF more
convenient. Fat-soluble vitamins need to be taken at the
same time as a meal for which pancreatic enzymes are
required.
13. Mineral and trace element supplementation
13.1. Minerals
Sodium and chloride supplementation is usually not
necessary except during exercise in hot climates when
extra salt is recommended (for minimal need see Table
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Table 5
Recommendations for vitamin supplements in CF
Fat soluble CF patients Starting dose
vitamins needing supplements
A EPI 4000–10 000 IU ydaya
D EPI, northern countries 400–800 IU ydayb
depending on serum level
E All 100–400 IU ydayc
K EPI, cholestasis 1 mgyday to 10 mgyweek
B12 Schilling test -45% 100 m i.m.ymonth
after ileal resection
Other water soluble None if dietary intake is normal
vitamins
EPI, exocrine pancreatic insufficiency. Conversion factors: IU to mg: vitamin A: IU=0.3sm; vitamin D: IUy40sm; vitamin E: all-rac-a-a b c
tocopheryl acetate: IUsmg; RRR-a-tocopherol: IUy1.49smg.
The need for vitamin supplementation in pancreatic sufficient patients should be assessed on an individual basis according to plasma levels.
2). Moreover, breast fed infants are not always able to
meet their sodium chloride needs and may require
supplementation, particularly when exposed to high
ambient temperatures or at high water losses due to
fever, sweating or tachypnoea. Children and adults with
CF need oral calcium supplementation if their diet is
found to be deficient.
During long-term treatment with aminoglycosides and
severe malabsorption patients with CF may need extra
substitution of magnesium.
13.2. Trace elements
The need for iron supplementation should be deter-
mined by the plasma transferrin saturation and not given
simultaneously with pancreatic enzymes. In growth
retardation and severe steatorrhoea zinc should be sup-
plemented. Selenium supplements may be needed in
special areas (e.g. in Switzerland, Austria). However,
these should be used with caution, as there is a narrow
range between supplementary and toxic doses.
14. Supplementation with antioxidants
Vitamin E is the most important fat-soluble antioxi-
dant and the doses recommended for supplementation
are presented above. However, higher doses will be
required if the intake of polyunsaturated fatty acids
(such as DHA) is increased above the average dietary
intake. Supplementation with vitamin C and selenium,
which represents an integral constituent of the antioxi-
dant enzyme glutathione peroxidase, and glutathione
precursors or derivatives need to prove to be beneficial
but randomised controlled studies are required before
their use can be recommended.
15. Refeeding the malnourished child
In many CF studies a relationship has been shown
between body weight and lung function w216x, but it is
unclear what is cause and what is effect w217x. Reasons
for a decrease in energy intake include anorexia, feeding
disorders (neonatal tube feeding), depression, interac-
tions with parents, oesophagitis, DIOS, iatrogenic fat
restriction, decreased appetite by concomitant drugs or
pulmonary inflammation and lack of general well being.
In most cases early intervention is extremely important
to prevent negative long-term effects. Intervention is
often complicated because the multifactorial nature of
the problem.
Interventions include behavioural treatment, psycho-
logical support, dietetic advice, oral supplementation,
nasogastric tube feeding, gastrostomy feeding and par-
enteral feeding. Although there are reports that eating is
a problem for patients with CF w218x, a positive effect
of any form of nutritional intervention with oral supple-
ments is still unproven w219,220x possibly due to small
and uncontrolled studies which differ in design, para-
meters and outcome measures. It is important to start
interventions early w217x (Table 1).
15.1. Recommendations
15.1.1. Oral feeding
0–1 year: Breast feeding is the preferred way of
feeding infants and also should be recommended for
those with CF. Mothers of breast-fed infants may need
to be encouraged to feed more frequently to increase
milk formation and thus meet their infant’s energy needs.
Some breast fed infants may benefit from sodium
chloride supplementation, particularly at high ambient
temperatures or with increased water losses due to fever,
diarrhoea, tachypnoea or increased sweating.
Formula fed infants will usually receive regular for-
mula that can be supplemented with up to a total
carbohydrate content of 10–12 gy100 ml and a total fat
content of 5 gy100 ml which will achieve an energy
density of approximately 1 kcalyml. Supplementation
should be gradually increased up to these levels. A
special dietetic product for infants with a high energy
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content could also be used but may be less flexible and
more expensive. The volume of feed should be adapted
to achieve normal weight gain and growth velocity,
which often means that higher volumes will need to be
fed than in healthy babies. Solids should be introduced
at the normal age of 4–6 months. Most infants with CF
will thrive satisfactorily on a normal weaning diet. If
the infant is failing to thrive, higher fat foods may be
used, with appropriate adjustment of the pancreatic
enzymes.
2–5 years: A normal to high fat diet should be
advised depending on growth and nutritional status. In
the past oral supplements were often unpalatable, how-
ever, recent studies show that some supplements are
well accepted by this age group. A compromise must
be found between palatability, volume and the optimal
composition to obtain maximal compliance. For children
in this age range specific commercially products are
available now.
5 years: Standard adult supplements can be used and
the choice is often directed by the taste of the patient
and long-term acceptance. Preferably, high energy den-
sity formulae should be used.
15.1.2. Supplements
There are many types of nutritional supplements
available. Palatability, volume and the optimal compo-
sition determine the choice. For children of approxi-
mately 1–5 years age specific commercially available
products can be used. Standard adult supplements are
suitable for children over 5 years. The choice of the
supplement is often determined by the taste preference
of the patient to obtain maximal compliance. High-
energy dense preparations should be used wherever
possible.
Supplements should be given before or after meals or
before bedtime to ensure that the appetite for normal
food is maintained. At the present time there is a lack
of evidence to support the use of dietary supplements
w219x. A large multicentre trial is currently addressing
this issue in the UK.
15.1.3. Tube feeding
Tube feeding can be administered by naso-gastric tube
or by gastrostomy, patient’s preference determining the
choice of the route. Preferably, tube feeding should be
given overnight with the aim to maintain normal dietary
intake during the day. Gastro-oesophageal reflux (GER)
may be a problem in some patients and should be
monitored closely before feeding is recommended. If
GER is documented, a Nissen’s fundoplication may be
indicated prior to gastrostomy insertion. In patients with
borderline glucose intolerance nocturnal hyperglycaemia
should be monitored and if necessary treated with
insulin. Normally, a high calorie non-elemental formula
can be used. If this is not tolerated, and in rare instances,
individual patients may benefit from elemental or medi-
um chain triglyceride (MCT) containing formulae.
Because of the slow flow of fat infusion absorption is
generally adequately controlled by taking a small dose
of enzymes at the start and during the feed. If patients
awake spontaneously they can also take extra enzymes
during night.
15.1.4. Total parenteral nutrition
Total parenteral nutrition is not recommended for
long-term treatment, but may be useful for short term
support in infants and children after major (GI) surgery
and in the severely ill patient waiting for a lung or liver
transplant. Several studies have shown an improvement
in nutritional status with supplementary parenteral feed-
ing w221,222x.
16. Treatment of the malnourished adult
The goal of treating the malnourished adult is to
increase lean body mass w21x. Initially a high fat and
high calorie diet may be used, but oral supplements are
often needed. Oral supplements should be highly palat-
able and provide a large amount of calories in a small
volume, preferably by having a high content of fat. The
main disadvantage of oral supplements is their influence
on normal appetite, thereby adversely affecting the
energy intake. However, the use of palatable high calorie
oral supplements showed an overall increase in daily
energy intake. If dietary interventions, including oral
supplementation, fail to increase bodyweight, one should
consider nasogastric tube or gastrostomy feeding (PEG).
Percutaneous sonographic gastrostomy (PSG) can be
performed under local anaesthesia by an experienced
radiologist guided by ultrasound w223x or by a gastro-
enterologist using fluoroscopic guidance. Enteral feeding
offers the possibility of feeding overnight, thereby not
influencing the patients’ appetite during the day
w224,225x. The formula used for tube feeding may be
non-elemental provided that enzymes are taken at the
start and preferably during the nocturnal feeding w226x
(see Section 15.1). Parenteral nutrition is generally not
recommended since it is limited by volume, immobilises
the patient and increases the risk of sepsis w227x. For
these reasons the use of parenteral nutrition is usually
restricted to when the GI tract is non-functional or in
severely malnourished patients awaiting transplantation.
When hyperalimentation is given as the sole interven-
tion in malnourished adult patients with CF, body weight
will increase but lean body mass may remain unchanged
w228x. Since increase of muscle mass is an important
target, the combination of nutritional support with spe-
cific muscle stimulation appears a relevant option. Com-
bining nutritional support with an exercise programme
may result in an increase in lean body mass, maximal
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ventilatory capacity, oxygen uptake and maximal exer-
cise capacity w229–231x.
17. The important questions and answers
Q1. Does a nutritional deficit exist in CF patients
and, if so, what impact does it have on disease progres-
sion and survival?
A1. Many patients with CF present with below normal
weight andyor height. Even with treatment, malnutrition
may occur leading to reduced weight gain and growth
and nutritional deficiencies, which are associated with a
more rapid progression, the disease and shortened sur-
vival. Nutritional deficits may be responsible for the
delay in the onset of puberty and menarche in teenagers
with CF. The nutritional state of patients has steadily
improved over the years and is likely to be one of the
major factors contributing to the increased survival in
recent years. Provided the chest infection and associated
inflammation are treated effectively, prevention and
early treatment of nutritional deficits are associated with
improved growth and respiratory function and are likely
to improve prognosis.
Q2. How does malnutrition present in CF and how
do we measure it?
A2. Malnutrition may present as underweight, sub-
normal longitudinal growth, or deficiencies in one or
more single nutrients. Underweight is defined as a
weight for height of less than 90% using appropriate
normal values for the population or in adults, body mass
index of less than 18.5 kgym . In children, BMI values2
should be interpreted on the basis of gender-specific
centile charts or Z scores. Standard deviation scores give
similar information and are more convenient for statis-
tical calculations. In the absence of normal values the
longitudinal assessment of nutrition and growth is par-
ticularly important. Knowledge of the puberty state is
necessary for the adequate assessment of growth over
the age of 10 years. Assessment of diet, clinical and
laboratory indicators of nutritional status should be
performed at least annually. A longitudinal assessment
is important.
Q3. What are the causes of malnutrition in CF?
A3. Malnutrition in CF has several causes including
intestinal malabsorption, inadequate intake and increased
energy requirements. Maldigestion and malabsorption,
particularly of fat and protein, are early and severe in
most patients. The most important cause is pancreatic
insufficiency with inadequate secretion of enzymes and
bicarbonate; other factors include impaired mucosal
uptake, altered motility, liver disease and bile salt abnor-
malities and structural abnormalities due to previous
bowel surgery. Energy intake may be inadequate due to
poor appetite secondary to chronic pulmonary and gas-
trointestinal disease, acute infection or psychosocial
problems causing abnormal eating behaviour. Energy
requirements are increased due to chronic infection and
inflammation, the excessive work of breathing and
possibly secondary to the primary genetic defect.
Q4. Are essential fatty acids reduced in plasma and
tissues of CF patients, and which mechanisms are
responsible?
A4. Many CF patients have low plasma and tissue
contents of linoleic acid and of omega-3 long-chain
polyunsaturated fatty acids, such as eicosapentaenoic
acid and docosahexaenoic acid. Omega-6 long-chain
polyunsaturated fatty acids such as arachidonic acid are
more variable. These changes have been related to a
variety of physiological impairments and adverse effects
and are considered as essential fatty acid deficiency.
Possible mechanisms that lead to polyunsaturated fatty
acid depletion include fat malabsorption, underweight
and negative energy balance with an increased beta-
oxidation of polyunsaturated fatty acids, and enhanced
peroxidative destruction of polyunsaturated fatty acids
due to poor antioxidant status and high oxidative stress.
Moreover, the conversion of essential fatty acids to
long-chain polyunsaturated fatty acids may be altered,
and linoleic acid turnover and arachidonic acid release
from phospholipids may be increased.
Q5. Is there evidence for vitamin deficiency?
A5. Blood levels of fat-soluble vitamins are frequently
low in patients with CF. Biochemical evidence of vita-
min A, vitamin D, vitamin E and vitamin K deficiency
is frequently found even in the absence of clinical
symptoms. Deficiencies of water-soluble vitamins are
rare.
Q6. Is there evidence for mineral and trace element
deficiency?
A6. Patients with CF are at risk of salt depletion and
metabolic alkalosis in particular during fever, hot weath-
er and exercise. They may suffer from mineral and trace
element deficiency, including chloride, sodium, calcium,
magnesium, zinc, iron and selenium.
Q7. What is the strategy to prevent malnutrition?
A7. Early diagnosis of CF by neonatal screening and
early recognition of CF specific complications and non-
CF related disorders, followed by appropriate treatments
in specialised CF centres including optimal treatment of
pulmonary infection, is recommended. There should be
frequent and regular surveillance of the patients includ-
ing expert dietary advice. For dietary intake in the first
year of life the ESPGAN recommendations should be
followed including exclusive breast-feeding in the first
4–6 months of life but if necessary a normal infant
formula can be used. If the child fails to thrive, early
intervention is mandatory. If children are gaining weight
normally on a normal diet this can be continued. No fat
limitations and no advice to increase fibre intake should
be given. At all ages there should be close attention to
behavioural factors, which may compromise adherence
to medical treatment and food intake. Patients on special
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diets (e.g. vegetarians) should be monitored particularly
closely.
Q8. Does aggressive treatment of pulmonary disease
in CF influence nutritional state?
A8. Malnutrition, infection, inflammation and dis-
turbed immune function create a vicious cycle in which
each factor in turn may exacerbate the other. Effective
treatment of lung infection has been demonstrated to
improve the nutritional status.
Q9. Does treatment of the nutritional status influence
lung disease?
A9. Nutritional interventions have been shown to
inhibit the decrease in lung function, thereby improving
survival in patients with CF.
Q10. How do we treat pancreatic insufficiency?
A10. All patients with CF who have evidence of
malabsorption due to pancreatic insufficiency should be
treated with pancreatic enzymes using standard prepa-
rations. Special attention has to be paid to other condi-
tions if fat malabsorption, poor growth or underweight
persist in spite of adequate dosing. Recommendations
are summarised in Tables 3 and 4.
Q11. What is the significance of fibrosing colonopa-
thy (FC)?
A11. Although the exact pathophysiology of FC is
still unknown, the progressive increase in enzyme dose
in response to persisting symptoms was a major factor
in reaching the very high doses implicated in the cause
of fibrosing colonopathy. Enzyme doses in excess of
10 000 IU lipaseykg per day should only be used with
caution and after excluding other causes of malabsorp-
tion and persisting gastrointestinal symptoms.
Q12. Is there an influence of ursodeoxycholic acid
(URSO) on nutritional status in CF patients with CF
related liver disease?
A12. URSO may enhance biliary bicarbonate secre-
tion and bile flow. Some studies have provided indica-
tions for positive effects of URSO on biochemical
parameters indicating liver disease, the bioavailability
of dietary lipids and lipid soluble vitamins, and on
weight gain which deserve further evaluation.
Q13. Is there a role for treatment strategies targeting
essential fatty acid status in CF patients?
A13. Dietary treatment of CF patients should aim at
avoiding subnormal levels of essential fatty acids and
long-chain polyunsaturated fatty acids. Energy, antioxi-
dants and polyunsaturated fatty acids of both the omega-
6 and the omega-3 series should be adequately supplied
in balanced proportions. Fish oil preparations have an
anti-inflammatory effect. Their effect on pulmonary
function deserves further evaluation. Similarly, benefi-
cial effects of high amounts of DHA in CF mice need
to be substantiated in CF patients. CF patients should
consume omega-3 fatty acids in amounts as recom-
mended for the general population.
Q14. What vitamins need to be supplemented, in
which doses and how?
A14. In general fat-soluble vitamins should be given
to patients with CF. Recommended doses are given in
Table 5. Vitamins should be given with a fat containing
meal and pancreatic enzymes. The dose of the vitamins
should be sufficient to achieve and maintain normal
blood concentrations. While there is little risk of over-
dosing with vitamins E and K, caution is necessary for
vitamins A and D.
Q15. What minerals and trace elements need to be
substituted?
A15. During exercise, in hot environments and during
fever, sodium and chloride supplementation is recom-
mended. During long-term treatment with aminoglyco-
sides patients with CF may need additional magnesium.
Iron and zinc deficiency should be corrected and results
controlled biochemically.
Q16. How should we re-feed the malnourished child?
A16. In case of malnutrition or weight loss there
should be a full re-evaluation of all the possible causes
that may affect the nutritional state. If nutritional inter-
vention is indicated, guidelines can be used. The first
approach should be to ensure maximal energy intake
using normal or energy-dense foods. Recommendations
are given in the table. Supplements should be given
between or after meals or before bedtime to ensure that
the appetite for normal food is maintained. Tube feeding
can be administered by naso-gastric tube or by gastros-
tomy, patients’ preference determining the choice of the
route. Preferably, tube feeding should be given overnight
with the aim to maintain normal dietary intake. Total
parenteral nutrition is only recommended for special
indications.
Q17. How do we re-feed the malnourished adult?
A17. The indication for supplemental feeding either
by oral supplements or tube feeding is the same in
adults as in older children and adolescents. Monitoring
for impaired glucose tolerance is needed. Psychosocial
issues including body image should be addressed. An
exercise-training program with the aim to increase lean
body weight should accompany re-feeding in adoles-
cents and adults.
Q18. Should anabolic steroids be used in re-feeding
the malnourished CF patient?
A18. In a very limited number of CF patients it has
been shown that megestrol acetate, a progestagon, may
temporarily lead to an increased appetite, an increase in
body weight with an increase in lean body mass and
pulmonary function. Disadvantages are the possible
development of diabetes, inhibition of growth, adrenal
suppression, cardiomyopathy and behavioural problems
including depression. Because of the side effects and
the limited data available, anabolic medication should
not be used in routine clinical practice.
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Q19. Which future studies should be carried out to
find more evidence for optimal nutrition in CF?
1. Long-term studies concerning the effect of antioxi-
dants, particularly studies involving vitamin E, C,
b-carotene and selenium, on clinical progress, res-
piratory function and nutritional status.
2. Long-term supplementation studies measuring vita-
min K status and bone mineral density. The relation-
ship between antibiotic therapy, gut flora and vitamin
K status should be studied. In general drug-nutrient
interactions should be determined and studied.
3. Quality vs. quantity in nutritional support.
4. Eating disorders and behaviour—categorisation, pre-
vention, treatment and intervention studies.
5. Factors affecting adherence to enzyme therapy.
6. Reasons for failure to correct levels of nutrients.
7. Optimal levels of various nutrients for people with
CF.
8. Evaluation of appetite stimulants.
9. Value of new prokinetic drugs.
10. Benefit of specific anti-inflammatory treatment, e.g.
anti-TNF.
11. Role of leptins in cystic fibrosis.
12. Value of high-energy oral supplements.
13. Ideal feeds for enteral feeding.
14. Best enzyme regimen for overnight feeds.
15. Possibility of delaying pancreatic insufficiency.
16. Role of acid suppression in improving steatorrhoea.
17. Optimal prevention and management of
osteoporosis.
18. Confirmation and study of reduced head circumfer-
ence brain development and fatty acid status during
infancy.
19. Early intervention in the development of diabetes
mellitus. At what stage do we intervene?
20. Use of anabolic steroids.
21. Treatment with DHA or fish oil.
22. Role of probiotics in nutrition and infection.
23. Effect on nutritional status of continuous antimicro-
bial treatment, started soon after diagnosis following
neonatal screening.
24. Optimisation of oral supplements.
25. Further knowledge of the homeostasis of calcium,
the lipid peroxidation and role of selenium and zinc
deficiency in young children.
26. The potential effects of URSO on nutritional status,
in subgroups of patients with CF who have different
disease states and conditions.
27. The effects of supplying increased intakes of specific
fatty acids, and of groups of fatty acids such as
long-chain omega-3 fatty acids, should be evaluated.
28. Relationship of fatty acids and immune functions
and neurological development.
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